Park L S, Friend D, Sassenfeld H M, Urdal D L
J Exp Med. 1987 Aug 1;166(2):476-88. doi: 10.1084/jem.166.2.476.
125I-labeled recombinant human B cell stimulatory factor 1 (BSF-1) was used to characterize receptors specific for this lymphokine on in vitro cell lines representing human B, T, and hematopoietic lineages, as well as on adherent cell lines of epithelial and endothelial origin, and on primary human gingival fibroblasts. BSF-1 binding was extremely rapid and saturable at both 4 and 37 degrees C, with a slow dissociation rate. On all human cell types examined, BSF-1 bound to a single class of high-affinity receptor (less than 3,000 receptors per cell) with a Ka of 0.5-1.0 X 10(10)/M. Human BSF-1 also bound to cell lines of simian but not murine origin. Comparison of kinetic characteristics obtained with a yeast-derived hyperglycosylated form of BSF-1 (Mr 60,000) and N-glycanase-treated, sugar-free BSF-1 (Mr 15,000) showed no significant differences. Among a panel of lymphokines and growth hormones, only unlabeled human BSF-1 was able to compete for the binding of 125I-labeled human BSF-1. Affinity crosslinking experiments resulted in the identification on both Raji cells and on primary human gingival fibroblasts of a receptor subunit with an average Mr of 139,000. These studies show that the BSF-1 receptor on human cells has an extremely broad cellular distribution, while further supporting the notion that the ability of BSF-1 to mediate a spectrum of biological activities cannot be accounted for by overt differences in the receptor for this lymphokine on different cell lineages.
用125I标记的重组人B细胞刺激因子1(BSF-1)来鉴定这种淋巴因子在代表人类B细胞、T细胞和造血细胞系的体外细胞系上,以及在上皮和内皮来源的贴壁细胞系和原代人牙龈成纤维细胞上的特异性受体。BSF-1的结合在4℃和37℃时都极其迅速且可饱和,解离速率缓慢。在所有检测的人类细胞类型上,BSF-1都与一类高亲和力受体(每个细胞少于3000个受体)结合,其解离常数Ka为0.5 - 1.0×10(10)/M。人BSF-1也与猿猴来源而非小鼠来源的细胞系结合。对酵母来源的高糖基化形式的BSF-1(Mr 60,000)和经N-糖苷酶处理的无糖BSF-1(Mr 15,000)所获得的动力学特征进行比较,未显示出显著差异。在一组淋巴因子和生长激素中,只有未标记的人BSF-1能够竞争125I标记的人BSF-1的结合。亲和交联实验在Raji细胞和原代人牙龈成纤维细胞上均鉴定出一种平均Mr为139,000的受体亚基。这些研究表明,人类细胞上的BSF-1受体具有极其广泛的细胞分布,同时进一步支持了这样一种观点,即BSF-1介导一系列生物学活性的能力不能通过该淋巴因子在不同细胞系上的受体的明显差异来解释。